NewswireToday - /newswire/ -
Palo Alto, CA, United States, 2008/03/12 - Frost & Sullivan is launching a new end user study on outsourcing trends, perceptions, selection criteria, and other important dynamics to contract manufacturing organizations (CMOs).
The study includes detailed interviews with more than 150 executives within the pharmaceutical and biotechnology industry involved in outsourcing to CMOs, with the objective of elucidating opportunities and threats and providing a greater understanding for parties interested in competing in this market.
If you are interested in sponsoring, shaping or participating in the research for this study - Contract Manufacturing Organizations: What Pharmaceutical and Biotechnology Companies Want and How to Compete for their Business, then send an email to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. Upon receipt, we will then forward this information to our research team who will contact you at the above information.
"Understanding how outsourcers make decisions and evaluate providers is vital to services companies," notes Frost & Sullivan Industry Manager, Daniel Ruppar. "Analyzing feedback on these dynamics provides CMOs a sound basis for formulating an effective strategy to compete in the U.S. market."
The rapid growth of contract manufacturing presents both challenges and opportunities. Within the biotechnology market, there are concerns about capacity constraints as biopharma interest continues to expand. The potential for growth is huge in emerging markets where there is already a significant amount of primary contract manufacturing of active pharmaceutical ingredients (APIs). Specialty pharmaceutical companies, which have not invested much in building manufacturing capacity, are also driving the demand for CMO services.
This study will survey CMO customers to better understand their preferences and current and future outsourcing patterns. Other key objectives of the survey include: the ability to understand the decision making dynamics within organizations, identifying key parties involved in outsourcing initiation, recommendation, approval and CMO performance evaluation and understanding what services and business models are appealing to outsourcers in the industry. Both pharmaceutical and biotechnology contract manufacturing will be assessed in the scope of this research, with a focus on final dosage form manufacturing.
"Manufacturers that can better understand the service models and business attributes that appeal to pharmaceutical and biotechnology companies, can develop and refine their operations to best serve customer demand," says Ruppar. "With effective information partners, companies can take important steps to ensure and accelerate their future growth."
Contract Manufacturing Organizations: What Pharmaceutical and Biotechnology Companies Want and How to Compete for their Business is part of ongoing research conducted within the Pharmaceutical and Biotechnology market, which also includes research in the following areas: Contract Research and Manufacturing, Specialty Pharmaceuticals, Biopharmaceuticals, Vaccines, and Drug Delivery. Recent titles include: Global Biopharmaceutical Contract Manufacturing Markets, Global CRO Spending Trends, and U.S. Specialty Pharmaceuticals – Overview and Trends. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Analyst Interviews are available to the press.
Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.